As global markets navigate a complex landscape marked by mixed performances across major indices, investors are closely watching the impact of recent monetary policy decisions and geopolitical developments. With the Federal Reserve's rate cut and a temporary trade truce between the U.S. and China providing some relief, attention turns to identifying stocks that may be trading below their fair value estimates amid these shifting conditions. In such an environment, a good stock is often characterized by strong fundamentals, resilience in diverse market scenarios, and potential for growth despite broader economic uncertainties.

Name

Current Price

Fair Value (Est)

Discount (Est)

Verbio (XTRA:VBK)

€15.27

€30.30

49.6%

Takara Bio (TSE:4974)

¥913.00

¥1815.41

49.7%

Nokian Panimo Oyj (HLSE:BEER)

€2.455

€4.91

50%

Meitu (SEHK:1357)

HK$8.75

HK$17.27

49.3%

Lotte Tour Development (KOSE:A032350)

₩17060.00

₩34000.09

49.8%

LianChuang Electronic TechnologyLtd (SZSE:002036)

CN¥10.06

CN¥20.00

49.7%

KB Components (OM:KBC)

SEK41.00

SEK81.64

49.8%

EverProX Technologies (SZSE:300548)

CN¥93.50

CN¥185.35

49.6%

eDreams ODIGEO (BME:EDR)

€7.19

€14.19

49.3%

Alibaba Health Information Technology (SEHK:241)

HK$5.73

HK$11.29

49.3%

Click here to see the full list of 502 stocks from our Undervalued Global Stocks Based On Cash Flows screener.

Let's explore several standout options from the results in the screener.

Overview: Beijing Aosaikang Pharmaceutical Co., Ltd., with a market cap of CN¥17.74 billion, operates in the pharmaceutical industry, focusing on the development and production of medications.

Operations: The company's revenue segments include the development and production of medications within the pharmaceutical industry.

Estimated Discount To Fair Value: 22.4%

Beijing Aosaikang Pharmaceutical is trading at CN¥19.05, significantly below its estimated fair value of CN¥24.55, indicating potential undervaluation based on cash flows. The company reported strong earnings growth for the nine months ending September 2025, with net income rising to CN¥223.31 million from CN¥127.02 million a year ago and basic EPS increasing to CN¥0.24 from CN¥0.14, demonstrating robust financial performance amidst forecasted revenue growth exceeding market expectations.

Insights from our recent growth report point to a promising forecast for Beijing Aosaikang Pharmaceutical's business outlook.

Delve into the full analysis health report here for a deeper understanding of Beijing Aosaikang Pharmaceutical.

Overview: Kotobuki Spirits Co., Ltd. is engaged in the production and sale of sweets both in Japan and internationally, with a market cap of ¥286.81 billion.

Operations: The company's revenue segments include KCC with ¥21.95 billion, Sucrey contributing ¥30.66 billion, and Sales Subsidiaries generating ¥7.27 billion.

Estimated Discount To Fair Value: 45.1%

Kotobuki Spirits is trading at ¥1,904, well below its estimated fair value of ¥3,466.97, highlighting potential undervaluation based on cash flows. Despite a slow revenue growth forecast of 7.6% annually, earnings are expected to grow at 10.3%, outpacing the JP market's average. Analysts predict a 32.2% price increase, though the company's dividend record remains unstable and profit growth isn't considered significant by high-growth standards.

Our growth report here indicates Kotobuki Spirits may be poised for an improving outlook.

Click here and access our complete balance sheet health report to understand the dynamics of Kotobuki Spirits.

Overview: M&A Research Institute Holdings Inc. operates as an intermediary for mergers and acquisitions in Japan, with a market cap of ¥72.59 billion.

Operations: The company generates revenue through its intermediary activities in the mergers and acquisitions sector within Japan.

Estimated Discount To Fair Value: 35.1%

M&A Research Institute Holdings is trading at ¥1,305, significantly below its estimated fair value of ¥2,010.35. Despite volatile share prices and a modest revenue growth forecast of 14.4%, earnings are expected to grow at 17.5%, surpassing the JP market average. Recent strategic moves include a first-ever dividend declaration and substantial share buybacks totaling ¥6.71 billion, reflecting a strengthened financial base and commitment to shareholder returns while maintaining growth investments.

Our comprehensive growth report raises the possibility that M&A Research Institute Holdings is poised for substantial financial growth.

Click here to discover the nuances of M&A Research Institute Holdings with our detailed financial health report.

Unlock our comprehensive list of 502 Undervalued Global Stocks Based On Cash Flows by clicking here.

Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.

Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.

Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include SZSE:002755 TSE:2222 and TSE:9552.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com